Welcome to our dedicated page for Bowen Acquisition news (Ticker: BOWN), a resource for investors and traders seeking the latest updates and insights on Bowen Acquisition stock.
Bowen Acquisition Corp reports developments tied to its role as a special purpose acquisition company, including capital-structure updates, shareholder voting matters, governance actions and security-structure disclosures.
Company updates also include public-company reporting matters, such as Nasdaq notices related to delayed periodic reports, alongside material agreements and other SPAC disclosures involving trust-account, redemption or deadline-extension mechanics when applicable.
Bowen Acquisition Corp (NASDAQ: BOWN), a special purpose acquisition company, received a delisting determination letter from Nasdaq on July 15, 2025, due to multiple listing requirement violations. The company failed to maintain: $50 million minimum market value of listed securities, 1.1 million publicly held shares, $15 million market value of publicly held shares, and 400 total shareholders.
BOWN has until July 22, 2025, to appeal the decision to a Nasdaq Hearings Panel. Without an appeal, trading will be suspended on July 24, 2025. The company intends to request a hearing and a trading suspension stay while pursuing its planned business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp (NASDAQ: BOWN) has received a non-compliance notification from NASDAQ on May 28, 2025, due to failing to submit its Q1 2025 Form 10-Q quarterly report. The company has until July 28, 2025 to submit a compliance plan to NASDAQ. If approved, NASDAQ may grant BOWN an extension of up to 180 calendar days (until November 17, 2025) to regain compliance. While this notification does not immediately affect BOWN's NASDAQ listing, there is no guarantee the company will successfully regain compliance with listing requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.